Premium
Nisoldipine: A New Dihydropyridine Calcium‐Channel Blocker
Author(s) -
Mitchell Judith,
Frishman William,
Heiman Mark
Publication year - 1993
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1993.tb03902.x
Subject(s) - nisoldipine , dihydropyridine , nifedipine , medicine , calcium channel blocker , isradipine , angina , calcium channel , pharmacology , clinical trial , drug , heart failure , calcium , cardiology , myocardial infarction
Nisoldipine is a new calcium‐channel blocker of the dihydropyridine subclass, with a chemical structure similar to nifedipine. It has been used in clinical trials to assess its efficacy and safety in patients with hypertension, angina pectoris, and congestive heart failure. Similar to other dihydropyridines, nisoldipine is a potent peripheral and coronary dilator. The most optimal dosage regimen has not been established in clinical trials. The drug appears to have a favorable side‐effect profile.